• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); ClinVar=VCV000825904; Zygosity=Unspecified (from parent cell line).
  

PubMed=9593003; DOI=10.1086/515290
Chodosh J., Holder V.P., Gan Y.-J., Belgaumi A., Sample J.T., Sixbey J.W.
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype.
J. Infect. Dis. 177:1194-1201(1998)

PubMed=10022853; DOI=10.1128/mcb.19.3.1651; PMCID=PMC83959
Ruf I.K., Rhyne P.W., Yang H., Borza C.M., Hutt-Fletcher L.M., Cleveland J.L., Sample J.T.
Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.
Mol. Cell. Biol. 19:1651-1660(1999)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)